Mixed outcomes with novel targeted therapies for HER2-positive upper GI cancers
While a HER2-targeted bispecific antibody showed extended survival in pre-treated gastric cancers, TKI–immunotherapy combinations failed to confer a survival benefit
Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell carcinoma
In a phase III trial, lower doses of adjuvant radiotherapy plus docetaxel were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy, with an impact on quality of life
Next-generation CAR-T cells are in the pipeline
Novel approaches are being tested to overcome current challenges in the use of cellular therapies such as high toxicity and a complex manufacturing process
Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
Quality of Life data in immune oncology trials: from side note to centre stage?
Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment
Givastomig combined with immunochemotherapy shows clinical activity in metastatic gastro-oesophageal adenocarcinomas
Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated